Redeye expects positive momentum in InDex shares as the market's focus shifts towards the phase III-study rather than the dilution related to the pending transaction. InDex is raising SEK 533m at SEK 1,2 per share. However, valuation now appears low and we see a tremendous upside if cobitolimod shows competitive data in the first induction study.